AbbVie Inc. vs Unilever PLC: Strategic Comparison

This in-depth comparison examines AbbVie Inc. and Unilever PLC across revenue, market value, business model, competitive positioning, and long-term growth strategy. Whether you are researching AbbVie Inc. on its own, evaluating Unilever PLC, or weighing the two companies side by side, the breakdown below highlights where each company leads and where the gap between AbbVie Inc. and Unilever PLC is widest.

On the headline numbers, AbbVie Inc. reports annual revenue of $61.2B against $54.9B for Unilever PLC, while their respective market capitalizations stand at $451.5B and $151.9B. AbbVie Inc. is headquartered in United States and Unilever PLC operates from United Kingdom, and those different home markets shape how each company competes.

AbbVie Inc.: AbbVie began as the separated pharmaceutical arm of Abbott Laboratories and became one of the world's largest biopharma companies by using Humira cash flow to build a broader portfolio. The company now presents itself as a diversified specialty-medicine platform rather than a single-product story.

Unilever PLC: Unilever used to be described by breadth: hundreds of brands, many categories, many countries. The current strategy is the opposite: fewer brands, clearer ownership, more disciplined capital allocation, and a portfolio tilted toward higher-growth personal care and beauty.

AbbVie Inc. and Unilever PLC pursue distinct approaches to generating revenue, and understanding how each company operates is the foundation of any fair comparison between AbbVie Inc. and Unilever PLC.

AbbVie Inc. business model: AbbVie earns revenue from patented and specialty medicines sold globally through healthcare systems, insurers, distributors, specialists, hospitals, and aesthetics providers. Immunology is the largest segment, supported by neuroscience, oncology, aesthetics, eye care, and other therapeutics.

Unilever PLC business model: Unilever makes money by building and distributing branded consumer products through supermarkets, drugstores, convenience channels, emerging-market distributors, e-commerce, foodservice, and direct or prestige beauty channels. Scale in procurement, manufacturing, media buying, and route-to-market supports margins.

The durability of a company's moat often decides long-term winners. Here is how the competitive advantages of AbbVie Inc. stack up against those of Unilever PLC.

AbbVie Inc. competitive advantage: AbbVie's advantage comes from deep immunology scale, specialist sales relationships, strong cash flow, global clinical and regulatory capabilities, and a portfolio led by Skyrizi, Rinvoq, Botox, Vraylar, Imbruvica, Venclexta, and Elahere.

Unilever PLC competitive advantage: Unilever's advantage is a mix of trusted brands, emerging-market distribution, local manufacturing, repeat-purchase categories, Power Brand marketing scale, and deep category knowledge in personal care, home care, beauty, and foods.

Future prospects matter as much as current results. The growth strategies below explain how AbbVie Inc. and Unilever PLC each plan to expand from here.

AbbVie Inc. growth strategy: AbbVie's growth strategy is to expand indications for Skyrizi and Rinvoq, defend Botox and aesthetics, invest in neuroscience and oncology, use targeted acquisitions to add late-stage assets, and maintain disciplined cash generation after Humira's decline.

Unilever PLC growth strategy: Unilever is concentrating investment behind Power Brands, simplifying SKUs, growing beauty and wellbeing, improving execution in emerging markets, using social and digital marketing more aggressively, and reshaping the portfolio through divestitures and acquisitions.

A closer look at the financial trajectory of AbbVie Inc. and Unilever PLC rounds out the comparison.

AbbVie Inc.: AbbVie generated $61.160 billion in FY2025 net revenue, up 8.6% on a reported basis, with immunology contributing $30.406 billion. Q1 2026 revenue reached $15.002 billion, showing continued growth after the Humira patent cliff as Skyrizi and Rinvoq scaled.

Unilever PLC: Unilever's 2025 reported turnover was EUR 50.5 billion on a continuing-operations basis after Ice Cream was treated as discontinued. Underlying sales growth was 3.5%, with 1.5% volume and 2.0% price growth. This profile converts EUR 50.5 billion at an estimated 2025 average EUR/USD rate of 1.0875 for USD comparison.